Form 8-K - Current report:
SEC Accession No. 0001628280-25-019507
Filing Date
2025-04-24
Accepted
2025-04-24 08:57:49
Documents
16
Period of Report
2025-04-24
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20250424.htm   iXBRL 8-K 41233
2 EX-3.1 ex31amendmenttotherestatec.htm EX-3.1 15085
3 EX-99.1 ex991pressreleaserssapr242.htm EX-99.1 13450
7 x4logoaa.jpg GRAPHIC 4345
  Complete submission text file 0001628280-25-019507.txt   220681

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20250424.xsd EX-101.SCH 1785
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20250424_lab.xml EX-101.LAB 23451
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20250424_pre.xml EX-101.PRE 13583
18 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20250424_htm.xml XML 3200
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 25863839
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)